CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total operating revenue	$ 324,239	$ 252,483
Operating expenses
Goodwill impairment charges	16,867	9,944
Selling, general and administrative expense	113,851	119,689
Depreciation and amortization	5,873	4,411
Total operating expenses	401,257	334,434
Loss from operations	(77,018)	(81,951)
Other non-operating expense (income)
Interest expense, net	6,777	4,082
Change in fair value of derivative warrant liabilities	286	(1,843)
Change in fair value of earnout liabilities	(803)	(59,215)
Change in fair value of conversion option derivative liabilities	(878)	(24,200)
Gain on loan forgiveness	0	(183)
Other, net	704	(501)
Total other non-operating loss expense (income)	6,086	(81,860)
Loss before provision for income taxes	(83,104)	(91)
Income tax benefit (expense)	36	243
Net income (loss)	(83,068)	152
Net income (loss) per share attributable to common stockholders:
Net income (loss) attributable to common stockholders, basic	$ (67,877)	$ 68
Weighted-average number of shares outstanding, basic (in shares)	73,748,660	72,793,497
Net income (loss) per share attributable to common stockholders, basic (in usd per share)	$ (0.92)	$ 0
Net loss attributable to common stockholders, diluted	$ (67,877)	$ (16,980)
Weighted-average number of shares outstanding, diluted (in shares)	73,748,660	80,605,600
Net loss per share attributable to common stockholders, diluted (in usd per share)	$ (0.92)	$ (0.21)
Patient services
Revenue
Total operating revenue	$ 213,504	$ 166,785
Operating expenses
Direct costs	181,017	134,761
Dispensary
Revenue
Total operating revenue	103,835	79,343
Operating expenses
Direct costs	83,071	65,111
Clinical trials & other
Revenue
Total operating revenue	6,900	6,355
Operating expenses
Direct costs	$ 578	$ 518